[go: up one dir, main page]

MXPA03010162A - Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. - Google Patents

Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.

Info

Publication number
MXPA03010162A
MXPA03010162A MXPA03010162A MXPA03010162A MXPA03010162A MX PA03010162 A MXPA03010162 A MX PA03010162A MX PA03010162 A MXPA03010162 A MX PA03010162A MX PA03010162 A MXPA03010162 A MX PA03010162A MX PA03010162 A MXPA03010162 A MX PA03010162A
Authority
MX
Mexico
Prior art keywords
combination
inhibitor
pde
obstructive airways
airways diseases
Prior art date
Application number
MXPA03010162A
Other languages
English (en)
Inventor
Roisin A Armstrong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129396A external-priority patent/GB0129396D0/en
Priority claimed from GB0210240A external-priority patent/GB0210240D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA03010162A publication Critical patent/MXPA03010162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se relaciona con una combinacion de uninhibidor selectivo de PDE4 y un agente anticolinergico parala administracion simultanea, secuencia1 o por separado por lavia inhalada en el tratamiento de una enfermedad obstructivade l a s vias respiratorias u otras enfermedades inflamatorias,con la condicion de que el agente anticolinergico no sea unasal de tiotropio.
MXPA03010162A 2001-05-25 2002-05-24 Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. MXPA03010162A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29360601P 2001-05-25 2001-05-25
GB0129396A GB0129396D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination
GB0210240A GB0210240D0 (en) 2002-05-03 2002-05-03 Pharmaceutical combination
PCT/EP2002/005726 WO2002096463A1 (en) 2001-05-25 2002-05-24 A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
MXPA03010162A true MXPA03010162A (es) 2004-03-10

Family

ID=27256347

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010162A MXPA03010162A (es) 2001-05-25 2002-05-24 Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.

Country Status (25)

Country Link
US (1) US20040147544A1 (es)
EP (1) EP1395288A1 (es)
JP (1) JP2005508861A (es)
KR (1) KR20040007605A (es)
CN (1) CN1511042A (es)
AP (1) AP2003002909A0 (es)
BG (1) BG108382A (es)
BR (1) BR0209992A (es)
CA (1) CA2446613A1 (es)
CO (1) CO5640041A2 (es)
CR (1) CR7152A (es)
CZ (1) CZ20033150A3 (es)
EE (1) EE200300585A (es)
HU (1) HUP0400037A2 (es)
IL (1) IL158776A0 (es)
MA (1) MA27027A1 (es)
MX (1) MXPA03010162A (es)
NO (1) NO20035204D0 (es)
NZ (1) NZ529335A (es)
OA (1) OA12610A (es)
PA (1) PA8546001A1 (es)
PL (1) PL367085A1 (es)
SK (1) SK14312003A3 (es)
TN (1) TNSN03123A1 (es)
WO (1) WO2002096463A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20060189642A1 (en) * 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ES2300755T3 (es) * 2003-03-28 2008-06-16 Nycomed Gmbh Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias.
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
EP1713472A2 (en) * 2004-02-06 2006-10-25 MEDA Pharma GmbH & Co. KG Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
WO2005102344A1 (ja) * 2004-04-27 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
ES2311771T3 (es) * 2004-08-19 2009-02-16 Rottapharm S.P.A. Derivados en n-fenilbenzamida como farmacos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
AU2006224842B2 (en) 2005-03-16 2011-09-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
KR100696432B1 (ko) * 2005-08-31 2007-03-19 김용환 건강진단용 팬티
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2330047T3 (es) 2005-12-21 2009-12-03 MEDA PHARMA GMBH & CO. KG Combinacion de r,r-glicopirrolato, rolipram y budesonida para el tratmiento de enfermedades inflamatorias.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
CA2223624C (en) * 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

Also Published As

Publication number Publication date
AP2003002909A0 (en) 2003-12-31
EP1395288A1 (en) 2004-03-10
CZ20033150A3 (cs) 2004-06-16
SK14312003A3 (sk) 2004-08-03
US20040147544A1 (en) 2004-07-29
BG108382A (bg) 2004-12-30
OA12610A (en) 2006-06-09
PL367085A1 (en) 2005-02-21
CR7152A (es) 2004-02-23
JP2005508861A (ja) 2005-04-07
IL158776A0 (en) 2004-05-12
WO2002096463A1 (en) 2002-12-05
CO5640041A2 (es) 2006-05-31
BR0209992A (pt) 2004-04-06
NO20035204D0 (no) 2003-11-24
MA27027A1 (fr) 2004-12-20
NZ529335A (en) 2005-09-30
CN1511042A (zh) 2004-07-07
HUP0400037A2 (hu) 2004-04-28
CA2446613A1 (en) 2002-12-05
TNSN03123A1 (en) 2005-12-23
EE200300585A (et) 2004-04-15
PA8546001A1 (es) 2003-12-30
KR20040007605A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
MXPA03010162A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
MXPA03010787A (es) Un agonista del receptor a2a de adenosina en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
MXPA03010731A (es) Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas.
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
MY140021A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
PL1610787T3 (pl) Synergiczna kombinacja zawierająca roflumilast i środek antycholinergiczny wybrany z soli tiotropium do leczenia chorób układu oddechowego
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
TW200610529A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
EA200301140A1 (ru) Ингибитор pde4 и антихолинергический агент в комбинации для лечения обструктивных болезней дыхательных путей
AU3737901A (en) Use of pde v inhibitors
DK1581224T3 (da) Tiotropiumholdig lægemiddelsammensætning til inhalation
ECSP034864A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias